Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovion Inc.

This article was originally published in Start Up

Executive Summary

Tubal ligation is an effective means of permanent birth control, but the procedure itself is no picnic. Ovion Inc. hopes to overcome the body's tendency to overgrow implanted objects, with a fiber-coated stent delivered non-surgically into the fallopian tubes.

You may also be interested in...



Permanent Contraception

Given the huge impact that having a baby has on every aspect of a woman's life--and that of her mate--it's small wonder that a growing number of companies are aiming to offer Baby Boomers improved contraceptive choices. Some are developing devices to make the widely performed tubal ligation surgery, which renders women sterile, less invasive, more convenient and safer than it has been to date. At least one firm hopes to give men a chance to participate in family planning via reversible vasectomization.

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel